The mesolimbic dopaminergic system is a neuroanatomical key structure for reward and motivation upon which previous studies indicated that antidepressant drugs exert a stimulatory influence, via still unknown neurobiological mechanisms. Here we examined the effects of chronic administration of antidepressants of several classes (amitriptyline, desipramine, imipramine, fluoxetine and tranylcypromine) and repeated electroconvulsive shock treatments (ECT) on dopamine D 3 receptor expression in the shell of the nucleus accumbens, a major projection area of the mesolimbic dopaminergic system. Short-term drug treatments had variable effects on D 
Introduction
Considerable emphasis has been placed upon the putative role of nucleus accumbens dopamine systems in appetitive motivation and positive reinforcement. 1, 2 Hence, mesolimbic dopaminergic neurons projecting to the nucleus accumbens have been suggested to be involved in the neurobiology of depression and the therapeutic actions of some antidepressant drugs. [3] [4] [5] [6] This hypothesis postulates that decreased dopamine activity is involved in depression, while increased dopamine function contributes to mania. Accordingly, dopaminergic drugs (eg amphetamine or cocaine) can produce effects in humans that are remarkably similar to an idiopathic manic episode 7, 8 and the discontinuation of such drugs 9 or the acute administration of dopamine receptor antagonists can result in a psychopathological state similar to a depressive episode. 10 Clinical studies in depressed patients using [
123 I]IBZM-SPECT have found increased D 2 receptor binding in the striatum probably reflecting reduced dopamine function in depression. 11, 12 Furthermore, dopaminergic drugs such as the dopamine-uptake inhibitors amineptine, nomifensin and buproprion have been successfully used for treating major depression. [13] [14] [15] Chronic treatment with antidepressant drugs produces in rats a variety of changes in dopaminergic neurotransmission, most notably a sensitization of behavioral responses to agonists acting at dopamine D 2 /D 3 receptors within the nucleus accumbens, 6, 16 an increased electrophysiological activity of mesolimbic dopaminergic neurons, 17, 18 an increase in D 2 /D 3 receptor binding sites 19 and an increase in interstitial dopamine concentrations in the nucleus accumbens. 20, 21 Similar results have been obtained after chronic ECT. [22] [23] [24] The D 3 receptor is expressed mainly in the limbic ventral part of the striatal complex, particularly in the shell of the nucleus accumbens, 25, 26 thought to be involved in reward, emotional, and cognitive processes. 27 A recent study indicates that antidepressant drugs administered repeatedly enhance D 3 receptor binding. 28 In this study we have examined the changes in cerebral expression of dopamine receptors, as well as those in dynorphin and substance P, two neuropeptides whose expression is regulated by dopamine, in rats receiving various kinds of antidepressant treatment, including monoamine uptake inhibitors, a monoamineoxidase inhibitor and ECT. Since responses to antidepressant drugs emerge in humans after several weeks of treatment, we have compared the effects of these drugs produced by either acute or repeated administrations.
Materials and methods

Drug treatments
Male Wistar rats (IFFA Credo, l'Arbresles, France (180-200 g)) were housed in groups of five in a temperaturecontrolled room on a 12 h : 12 h light : dark schedule, light starting at 7.00 am, with free access to food and water. They received daily intraperitoneal injections (between 4.00 and 6.00 pm) of either desimipramine (15 mg kg −1 ) or imipramine (15 mg kg −1 ), amitriptyline (15 mg kg −1 ), fluoxetine (15 mg kg −1 ) or tranylcypromine (7.5 mg kg ) for 1, 5, 10, 21 or 42 days. Rats were killed by decapitation 24 h after the last injection and the brain rapidly removed and frozen by dipping in isopentane maintained at −30°C.
Electroconvulsive shocks
Electroconvulsive treatment (85 V, 50 Hz, 0.05 s) was administered using ear clip electrodes in non anesthetised rats once a day for 10 days. Each treatment caused a typical tonic clonic convulsion for 20-35 s. Sham treatment consisted in application of electrodes without current. Rats were killed 24 h after the last treatment and their brain rapidly dissected and frozen. 
In situ hybridization and receptor autoradiography
Statistical analysis
Values reported are means ± SEM. Differences between groups of animals treated with saline or antidepressant drugs were analyzed by one-way ANOVA followed by a Dunnett's multiple comparison post-hoc test when P Ͻ0.05. Analysis of variations of D 3 receptor mRNA with treatment duration was performed by two-way ANOVA followed by a Least Significant Difference test. Effects of electroconvulsive shocks were analysed by the Mann-Whitney U test.
Results
A daily regimen of antidepressant drugs of various chemical classes with different pharmacological profiles (see Table 1 After 21-day treatments, other mixed norepinephrine/ serotonin uptake inhibitors, ie desipramine and imipramine, as well as the monoaminoxidase inhibitor tranylcypromine all increased, like amitriptyline, D 3 receptor mRNA by 35-54% in the shell of nucleus accumbens, but fluoxetine produced an opposite effect (Table 1 ). In addition, some compounds also increased D 3 receptor mRNA in some other regions, ie desipramine in the fronto-parietal cortex, septum and olfactory tubercle and islands of Calleja. No changes were observed in the dorso-lateral striatum.
On the contrary, when imipramine, amitriptyline and tranylcypromine were administered only once, they elicited a decrease in the D 3 receptor mRNA level in the shell of nucleus accumbens; imipramine also decreased D 3 receptor mRNA in the islands of Calleja ( Table 2 ). Analysis of the changes produced during prolonged treatment by amitriptyline ( Figure 2 ) indicated that after an initial reduction, D 3 receptor mRNA in the shell of nucleus accumbens was rapidly normalized within 5 days, was progressively and maximally enhanced after a 21-day treatment, and had returned to normal levels after a 42-day treatment. Changes in D 3 receptor mRNA followed the same evolution in the islands of Calleja, and were more precocious in the core of nucleus accumbens ( Figure 2 ).
In contrast, fluoxetine produced changes in opposite directions as compared with the other antidepressant drugs (Tables 1, 2 and Figure 2 ). Thus, D 3 receptor mRNA in the shell of nucleus accumbens was initially enhanced after a single administration, returned to normal levels within few days, was decreased after a 21-day treatment and had returned to normal levels after a 42-day treatment. There were similar changes in the core of nucleus accumbens, but no significant changes in the islands of Calleja (Figure 2) .
In order to assess whether the changes observed in D 3 receptor mRNA levels were accompanied by changes in the receptor protein, binding of [ 3 H]7-OH-DPAT, a selective D 3 receptor ligand 26 was measured. These experiments were designed in such a way that they allowed us to quantify D 3 receptor binding in absolute amounts, and thus to assess the changes after repeated handling and/or injections with saline ( Figure  3 ). In fact, such treatment with either saline or antidepressant drugs produced a marked time-dependent reduction of [ 3 H]7-OH-DPAT binding in the shell of nucleus accumbens (F 2,26 = 30.76, P Ͻ 0.0001 by twoway ANOVA, see Figure 3 ), core of nucleus accumbens (F 2,26 = 4.053, P = 0.029, see Figure 3 ) and islands of Calleja (F 2,26 = 4.270, P = 0.0497, not shown). For example, [ 3 H]7-OH-DPAT binding after a 42-day treatment by saline was reduced by 44% (P Ͻ 0.001) and 33% (P Ͻ 0.01) in the shell and core of nucleus accumbens, respectively, compared with the levels after a 10-day treatment. In the shell of nucleus accumbens, there was an overall effect of treatment (F 2,26 = 11.58, P = 0.00025 by two-way ANOVA) by amitriptyline or fluoxetine, and significant time × treatment interaction (F 4,26 = 3.465, P = 0.021), which means that the antideMolecular Psychiatry pressant drugs slowed down the time-dependent decrease in D 3 receptor binding. Post-hoc analysis indicates that both amitriptyline and fluoxetine had significant effects after a 42-day treatment (P Ͻ 0.05). In the core of nucleus accumbens, the effects were essentially the same as in the shell of nucleus accumbens, although much limited in amplitude, the effects of fluoxetine being not statistically significant.
We also examined whether the observed changes produced by antidepressant drugs were specific to the D 3 receptor (Table 3) . Imipramine and amitriptyline increased the D 1 receptor mRNA level in the shell of nucleus accumbens and the caudate-putamen, but desipramine and tranylcypromine were inactive. Imipramine and amitriptyline increased the D 2 receptor mRNA level, but only in the caudate-putamen. Fluoxetine was unable to change D 1 or D 2 receptor mRNA levels in either direction.
We next examined the effects of a 21-day treatment with amitriptyline or fluoxetine on substance P and dynorphin mRNA levels known to be regulated by D 1 and D 3 receptors. 29, 30 Both amitriptyline and fluoxetine significantly increased substance P (+ 67% and + 94%, respectively), but not dynorphin mRNA level, and this effect was restricted to the ventral part of shell of nucleus accumbens, the region where the D 3 receptor is expressed (Table 4) . accumbens were not significantly changed by ECT treatment (not shown): in treated animals, mRNA levels were 96 ± 6% (P = 0.45 by the Mann-Whitney U test) and 84 ± 14% (P = 0.28) of the control values for D 1 and D 2 receptors, respectively.
Discussion
In spite of the long-standing clinical use of antidepressant drugs, the neural mechanisms underlying the therapeutic effect of these drugs are still incompletely understood. Most antidepressant drugs are active after acute administration in mouse behavioral tests predicting antidepressant activity, such as the forced
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swimming test 31 and the tail suspension test. 32 However, the antidepressant effect emerges in patients after chronic but not acute treatment, enlightening the crucial importance of adaptive changes in promoting this activity. Moreover, the various antidepressant drugs have different primary pharmacological targets, which makes it difficult to define a final common mechanism of action, and the situation is even less clear regarding other antidepressant treatments such as ECT. Our data show that selective increase in D 3 receptor binding or mRNA expression in the shell of nucleus accumbens accompanies all chronic antidepressant treatments that were studied here. Some features of the response to these antidepressant treatments suggest that enhanced dopamine neurotransmission through this receptor participates in the adaptive changes leading to antidepressant activity. One important feature is that antidepressant drugs, except fluoxetine, enhanced D 3 receptor mRNA after chronic (21-day), but not acute treatment; in addition, fluoxetine and amitriptyline enhanced D 3 receptor binding after a 42-day treatment, which is in agreement with the delayed therapeutic action of these drugs in depressed patients. Several antidepressant drugs had actually an opposite effect when tested after a single administration: imipramine, amitriptyline and tranylcypromine significantly reduced D 3 receptor mRNA in the shell of nucleus accumbens. Several other antidepressant drugs were previously shown to enhance D 3 receptor binding after chronic treatment (14 days, two injections per day), but to have much limited and variable effects after an acute injection. 28 Interestingly, fluoxetine, which markedly differed from other antidepressant drugs in its effects on D 3 receptor mRNA, especially after short chronic treatment, also increased D 3 receptor protein in the shell of nucleus accumbens after a 42-day chronic treatment, suggesting a delayed Molecular Psychiatry action in rats as compared with other antidepressant drugs. A short-term exposure to fluoxetine decreases dopamine extracellular levels, whereas other antidepressant drugs have an opposite effect; 20 this also exemplifies the fact that the acute effects of antidepressant drugs may not be relevant to their clinical efficacy. The discrepancies observed between the effects of antidepressant drugs on D 3 receptor binding and mRNA levels could be due to different turnover rates of mRNA and membrane proteins. In fact, adaptive mechanisms increasing degradation of short-lived mRNA could have progressively masked increased mRNA levels, when measured 24 h after the last drug administration. On the contrary, slowly increasing and long-lived receptor protein, together with a delayed action of fluoxetine, could account for the fact that significant effects of antidepressant drugs could be observed only after a long-term treatment. Thus, our results also suggest that receptor binding may be a better indicator than receptor mRNA for the effects of antidepressant drugs.
Whereas the various treatments used in the present study, including inhibitors with different selectivity for monoamine uptakes, a monoamine oxidase inhibitor and ECT, have most likely different short-term outcomes, they all increased D 3 receptor expression upon long-term repeated administration. These observations, together with those of a previous study showing that other antidepressant drugs increase D 3 receptor binding, 28 show that enhanced D 3 receptor expression is a common secondary action of antidepressant treatments. Moreover, this common effect is restricted to the shell of nucleus accumbens, that various studies have shown to subserve the role of dopamine in appetitive motivation, positive reinforcement, pleasurable effect of reinforcing stimuli 1,2 and therapeutic actions of some antidepressant drugs. [3] [4] [5] [6] Interestingly enough, ECT produced the most rapid and robust increase in D 3 receptor protein and mRNA expression, as compared to antidepressant drugs, which is in agreement with their therapeutic efficacy in refractory depression.
Although some antidepressant drugs elicit changes In the shell of nucleus accumbens this receptor is found expressed mainly in substance P-and dynorphin-expressing neurons 30, 36 and both neuropeptide expressions are influenced by pharmacological manipulations of D 1 and D 3 receptors in various experimental circumstances. 29, 30 In agreement with a previous observation, 37 we found that amitriptyline and fluoxetine increased substance P mRNA in the shell of nucleus accumbens, which might be the result of an increased D 3 receptor function. Since antidepressant treatments decrease substance P concentrations, 38 they may accelerate substance P turnover and release. Nevertheless, this hypothesis is hardly reconcilable with the antidepressant effect of a substance P receptor antagonist recently reported. 39 It has been repeatedly shown that antidepressant treatments in rats significantly influence dopamine function in the mesolimbic system by increasing the responsiveness of postsynaptic dopaminergic receptors (see Willner for a review). 6 Notably, the locomotor stimulants effects of the D 2 /D 3 receptor agonist quinpirole are enhanced by repeated treatments with various antidepressant drugs, 40 42 Finally, the role of D 3 receptor overexpression in one form of behavioral sensitization 29 is consistent with the idea that a similar process participates in the behavioral changes triggered by antidepressant treatments.
Importantly, our data also show a progressive and strong down-regulation of D 3 receptor binding by repeated handling and injections, even though no drug was administered. This change is not related to increasing age, which actually enhances D 3 receptor expression 43 and might be interpreted as a stressinduced effect. Actually the action of fluoxetine and amitriptyline were not strictly to enhance D 3 receptor binding in the shell of nucleus accumbens, but rather to counteract this downregulation, thus opposing the effects of stress. Accordingly, antidepressant drugs reverse chronic mild stress-induced decrease in the consumption of palatable sweet solutions, 44 an effect accompanied by increased D 2 /D 3 receptor binding 19 and D 3 receptor mRNA. 34 These results point to a role of the D 3 receptor in the adaptive changes induced by chronic stress, a major risk factor in depression, [45] [46] [47] [48] that antidepressant treatments may correct by their effects on D 3 receptor expression.
One can speculate about possible mechanisms by which chronic stress and antidepressant treatments regulate the D 3 receptor gene in opposite directions. Acute stress activates the mesocortical dopaminergic system, 49 but chronic stress triggers adaptive processes leading to decreased dopaminergic transmission in the shell of nucleus accumbens. 50, 51 On the contrary, antidepressant drugs 52 and ECT 53 induce a subsensitivity of dopamine autoreceptors, leading to a persistent enhancement of dopamine neuron electrical activity. 17, 18 Although antidepressant drug treatments have variable effects on basal extracellular dopamine in the nucleus accumbens, 54 they increase amphetamine-evoked dopamine release 21, 55 and ECT treatments enhance spontaneous dopamine release. 23 There is also some evidence for a decreased dopamine metabolism and turnover in depressed patients. 3, 11, 12 Hence, the data in the literature are rather consistent with a decreased activity of mesolimbocortical dopamine neurons by chronic stress and in depression, which is reversed by chronic antidepressant treatments. The convergent effects of antidepressant drugs with different serotonin/norepinephrine pharmacological selectivities on dopamine neuron activity can be explained as an adaptation of these neurons to the inhibitory actions of both serotonin and norepinephrine, suggested by various anatomical and functional studies (reviewed in Prisco and Esposito; and Grenhoff et al). 56, 57 We have previously shown that D 3 receptor expression, unlike that of other dopamine receptor subtypes, depends critically upon dopamine neuron activity, through the release of an anterograde factor different from dopamine itself and its known co-transmitters. 58 Thus, the opposite variations of dopamine neuron activity in response to chronic stress or antidepressant drug treatments may determine opposite parallel variations in D 3 receptor expression in the shell of nucleus accumbens. Recently, we provided evidence indicating that brain-derived neurotrophic factor (BDNF), a neurotrophin synthesized by dopamine neurons, 59 anterogradely transported and released by neurons upon depolarization, 60 is the factor controlling D 3 receptor expression. 61 In agreement with this contention, BDNF expression is reduced by stress 62 and elevated by chronic antidepressant treatments. 63 In conclusion, our study suggests that D 3 receptor expression and function are down-regulated in stress and, possibly, depression, and that these changes are reversed by antidepressant treatments. As a corollary, selective D 3 receptor agonists 42 may represent a new class of antidepressant drugs, a proposal supported by data showing that pramipexole, a preferential D 3 receptor agonist, 64, 65 displays antidepressant-like effects in animals 66, 67 and is efficacious as an antidepressant in humans. 68, 69 
